Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent advances in the diagnosis and management of female pattern hair loss but reports no new clinical results.

This review found mixed evidence regarding platelet-rich plasma's effectiveness in various medical applications, noting significant limitations like small sample sizes and lack of standardization that necessitate further research.

In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.

This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This article discusses the importance of clinical biopreservation for cells and tissues in hair transplantation and regenerative medicine, reporting no new empirical findings.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.

This research observed that Backhousia citriodora leaf extract effectively reduced sebum production and improved sebum composition across different ethnicities, significantly decreasing skin oiliness and the likelihood of shiny skin when used in a cream applied twice daily for 28 days.

This study found that stabilizing HIF1A in hair follicle cells promoted a shift to glycolysis, potentially reducing oxidative stress and promoting hair growth, particularly in balding dermal papilla cells.

This study found that infrared thermography might be a useful non-invasive tool to help diagnose frontal fibrosing alopecia by identifying active phases of the disease.

This study found that stabilizing HIF1A in balding hair follicle cells shifted their metabolism towards glycolysis, reducing oxidative stress and potentially promoting hair growth.

In this study, the authors found that a botanical extract with anti-inflammatory and anti-oxidative properties stabilized hair loss and preserved natural hair pigmentation and strength over six months.

This study found that intradermal injections of cultured autologous dermal sheath cup cells for androgenetic alopecia showed hair loss stabilization at 24 months without serious adverse effects and a sustained response in some participants.

This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.

This review examines the challenges of hair follicle regeneration and outlines strategies for bioengineering human hair follicle models, without presenting new experimental results.

This review examines current diagnosis and management strategies for hair loss in women with polycystic ovarian syndrome, reporting no new clinical findings and emphasizing the need for more targeted research in this area.

Combining scalp photos with hair density and caliber measurements gives a more accurate assessment of hair loss.

This study found no abstract is available, but it addresses potential interactions between oral minoxidil and alcohol, specifically the exacerbation of hangover symptoms.

The document concludes that more research is needed to confirm if COVID-19 vaccines cause a type of hair loss called alopecia areata.

This review highlights the promising potential of mesotherapy for delivering dutasteride and minoxidil as treatments for androgenetic alopecia, emphasizing the need for more research on drug preparation, delivery, and maintenance to establish its safety and effectiveness.

This review outlines the historical and ongoing evolution in understanding and treating alopecia areata, highlighting current research frontiers in genetics, immune mechanisms, and potential new treatments, but reports no new results.

This study highlights emerging regenerative strategies, such as stem cell-derived therapies and machine learning tools, that may advance hair loss treatment beyond traditional methods by promoting follicle regeneration and offering personalized care.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

This study reported that women with alopecia often face high out-of-pocket costs for over-the-counter treatments and camouflaging agents due to insufficient insurance coverage, which can significantly impact their financial well-being and ability to afford basic necessities.